Platform Partnerships Capitalize on Nu.Q technology through OEM partnerships and collaborations like the Sysmex alliance to accelerate platform adoption across global diagnostics markets. The collaboration demonstrates proof of concept for integrating epigenetics-based tests into established IVD workflows, creating scalable sales opportunities for lab networks and distributors.

Cross-Sector Upsell Leverage the multi-pillar Nu.Q portfolio (Vet, NETs, Discover, Cancer) to drive cross-selling across veterinary and human medicine. With a track record of veterinary applications and ongoing human clinical exploration, there is a natural path to expand customer lifetime value through bundled tests and multi-market licenses.

Early Detection Value Position the Capture-PCR based liquid biopsy as a rapid, cost-effective screening option for early disease detection, triage in suspected sepsis or cancer cases, and routine blood tests. Target hospitals, diagnostic labs, and public health programs seeking scalable blood-based tests that can improve triage accuracy and outcomes.

Global Footprint Highlight international footprint and ongoing licensing discussions with global diagnostic leaders to support multi-country deployments. Leverage regional presence in the US, Europe, and Asia to build local sales and support ecosystems, accelerating adoption and service capabilities.

IP & Deployment Capitalize on a growing IP portfolio, including Ebola triage patents, to attract strategic partners for deployment in outbreak zones and high-consequence settings. Use strong IP position to secure licensing deals and co-development opportunities with health agencies and large diagnostics players.